Skip to content

Our research

The research focus of the WA Kids Cancer Centre is on developing safe new treatments for childhood cancers, including brain cancer, sarcoma, leukaemia and neuroblastoma.

The research focus of the The Kids Cancer Centre is on developing safe new treatments for childhood cancers, including brain cancer, sarcoma, leukaemia and neuroblastoma.

The research of the The Kids Cancer Centre is undertaken by laboratory-based scientists, paediatric oncologists, computational biologists, and many higher degree (mainly PhD) and Honours students. Our research is organised into collaborative programs of laboratory-based and translational research.

Our goal is to discover new therapies - therapies that are more effective and less toxic - to fight the most aggressive cancers in babies and children. Our research focuses on:

  • Harnessing the power of the body's own immune system to fight cancer cells via immunotherapy.
  • Determining why apparently similar cancer cells from individual patients respond differently to treatment.
  • Testing existing drugs and new compounds to improve patient outcomes.
  • Understanding the biology of individual cancers to identify weaknesses to target with therapies.
  • Developing new treatments with industry partners to feed our drug development pipeline.

The WA Kids Cancer Centre has a game changing approach for fighting childhood cancer

Our research strategy is to use our world-first childhood cancer laboratory models to investigate potential new cancer immunotherapies and personalised medicines.

Immunotherapy is an exciting cancer treatment that works by engaging the body’s own immune response to fight the cancer. It promises to be an effective and safe cancer therapy that does not cause the collateral damage of conventional treatments. Immunotherapy has fulfilled this promise for adults with extraordinary results in some cancers. Sadly, the development of immunotherapy treatments for children falls far behind.

Personalised medicine involves performing detailed genetic analysis of individual children with cancer and using the information gained to treat them with drugs that are precisely targeted to the individual tumour. All children with cancer treated in Perth undergo such genetic testing, allowing us to use the genetics of individual’s tumours to inform both treatment development in the laboratory and clinical trial opportunities on the ward.

Our goal is to develop such promising and safe treatments to defeat childhood cancers and reduce the need for toxic chemotherapies and radiotherapies.

If you are interested in potential research collaborations, please contact us.

Latest

Videos

A Systematic Review on the Role of Postoperative Radiotherapy in Pelvic Ewing Sarcoma

Ewing Sarcoma of the pelvis has poorer outcomes than other anatomical sites, with complex anatomy often precluding resection with wide margins. The role of postoperative radiotherapy (RT) in improving outcomes remains undefined. A systematic review using Medline, Embase and Cochrane databases (1972-April 2024) evaluated postoperative RT's impact on local recurrence, event-free survival and overall survival. Twenty-nine retrospective studies (21 to 296 patients) met inclusion criteria, with 28 rated good quality.

Myeloablative Busulfan, Fludarabine and Melphalan Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Childhood Myeloid Malignancy

Allogeneic hematopoietic stem cell transplant (HSCT) is a proven curative therapy for children with high-risk myeloid malignancies. Disease relapse, transplant-related mortality and graft versus host disease (GvHD) are the main causes of treatment failure and death post-transplant. The optimum pretransplant conditioning regimen is yet to be defined. There is limited data regarding the use of busulfan, fludarabine and melphalan as a myeloablative conditioning regimen in children receiving HSCT for myeloid malignancies.

Clinical and germline risk factors for multiple treatment related toxicities in pediatric acute lymphoblastic leukemia

Pharmacological inhibition of sclerostin protects bone from B-cell acute lymphoblastic leukemia-mediated destruction

B-cell acute lymphoblastic leukemia (B-ALL) is the most common pediatric cancer. Current therapeutic regimens have improved 5-year event-free survival rates to 90%, however clinical outcomes for high-risk subgroups, such as BCR-ABL1+ B-ALL and relapsed ALL, remain poor. In addition, 16% of newly diagnosed children with ALL present with vertebral compression fractures. Moreover, 16% of children with ALL undergoing glucocorticoid therapy also experience a high incidence of vertebral fractures, indicating that bone health may be compromised by both leukemia progression and osteotoxicity of chemotherapy.

All publications